Compare · OBIO vs RGC
OBIO vs RGC
Side-by-side comparison of Orchestra BioMed Holdings Inc. (OBIO) and Regencell Bioscience Holdings Limited (RGC): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both OBIO and RGC operate in Medicinal Chemicals and Botanical Products (Health Care), so they compete in similar markets.
- RGC is the larger of the two at $10.04B, about 41.6x OBIO ($241.3M).
- Over the past year, OBIO is up 20.5% and RGC is up 25.1% - RGC leads by 4.6 points.
- OBIO has been more active in the news (11 items in the past 4 weeks vs 6 for RGC).
- OBIO has more recent analyst coverage (9 ratings vs 0 for RGC).
PerformanceOBIO+20.48%RGC+25.09%
2025-06-10+0.00%2026-06-09
- Company
- Orchestra BioMed Holdings Inc.
- Regencell Bioscience Holdings Limited
- Price
- $4.03+2.03%
- $20.09-6.90%
- Market cap
- $241.3M
- $10.04B
- 1M return
- -0.25%
- -30.97%
- 1Y return
- +20.48%
- +25.09%
- Industry
- Medicinal Chemicals and Botanical Products
- Medicinal Chemicals and Botanical Products
- Exchange
- NASDAQ
- NASDAQ
- IPO
- 2020
- 2021
- News (4w)
- 11
- 6
- Recent ratings
- 9
- 0
Latest OBIO
- Officer Hochman David P bought $19,150 worth of shares (5,000 units at $3.83), increasing direct ownership by 0.47% to 1,064,029 units (SEC Form 4)
- Officer Sherman Darren sold $58,050 worth of shares (15,000 units at $3.87) as part of a pre-agreed trading plan, decreasing direct ownership by 1% to 1,184,327 units (SEC Form 4)
- Orchestra BioMed Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
- SEC Form 144 filed by Orchestra BioMed Holdings Inc.
- Chief Financial Officer Taylor Andrew Lawrence covered exercise/tax liability with 3,076 shares, decreasing direct ownership by 0.49% to 629,417 units (SEC Form 4) (for tax liability)
- Officer Sherman Darren covered exercise/tax liability with 4,925 shares, decreasing direct ownership by 0.41% to 1,199,327 units (SEC Form 4) to satisfy tax liability
- Director Aryeh Jason bought $2,494 worth of shares (665 units at $3.75), increasing direct ownership by 0.57% to 118,118 units (SEC Form 4)
- Orchestra BioMed to Participate in the Jefferies Global Healthcare Conference
- Officer Hochman David P bought $18,850 worth of shares (5,000 units at $3.77), increasing direct ownership by 0.47% to 1,059,029 units (SEC Form 4)
- Director Aryeh Jason bought $34,987 worth of shares (8,971 units at $3.90), increasing direct ownership by 8% to 117,453 units (SEC Form 4)
Latest RGC
- SEC Form 4 filed by Director Lo William Wing Yan Dr
- SEC Form 4 filed by Director Hui Evana Yee Wah
- SEC Form 6-K filed by Regencell Bioscience Holdings Limited
- SEC Form 424B5 filed by Regencell Bioscience Holdings Limited
- SEC Form 6-K filed by Regencell Bioscience Holdings Limited
- SEC Form 6-K filed by Regencell Bioscience Holdings Limited
- SEC Form 6-K filed by Regencell Bioscience Holdings Limited
- SEC Form 6-K filed by Regencell Bioscience Holdings Limited
- SEC Form 6-K filed by Regencell Bioscience Holdings Limited
- SEC Form 6-K filed by Regencell Bioscience Holdings Limited